CardiovascularInvestigational

Urocortin 1

Intravenous

Overview

Urocortin 1 is a 40-amino acid peptide belonging to the corticotropin-releasing factor (CRF) family. It binds to both CRF receptor 1 and CRF receptor 2 with high affinity, mediating diverse cardiovascular effects including vasodilation, positive inotropy, and cardioprotection.

Mechanism of Action

The peptide has demonstrated beneficial hemodynamic properties and anti-inflammatory actions in preclinical models of heart failure and ischemia-reperfusion injury..

Research Summary & Key Findings

Early phase clinical trials have evaluated urocortin 1 infusion in heart failure patients, demonstrating hemodynamic improvements including increased cardiac output and reduced systemic vascular resistance. However, no large-scale efficacy trials have been completed, and development for cardiovascular indications remains investigational.

Clinical Status

Investigational

Urocortin 1 is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Urocortin 1 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Urocortin 1.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.